口腔状细胞癌的预后生物标志物:目前的证据和未来的方向
1Department of Oral and Maxillofacial Surgery, University Medical Center Goettingen, Goettingen, Germany.
Frontiers in oncology
|December 22, 2025
概括
口腔状细胞癌 (OSCC) 的预后是复杂的. 生物标志物与传统因素一起,改善风险预测,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 口腔状细胞癌 (OSCC) 呈现出不同的预后,需要先进的预测工具.
- 传统的分期系统可能无法完全捕捉个体患者的风险.
- 目前正在进行研究,以确定可靠的生物标志物用于OSCC预后.
研究的目的:
- 审查和综合有关OSCC恶性瘤和进展因子的当前文献.
- 检查基于分子和蛋白质的生物标志物的预后意义.
- 提供关于OSCC预后评估的未来方向的见解.
主要方法:
- 关于OSCC预后因素的现有研究的综合文献综述.
- 对与生存结果相关的临床,组织病理学,分子和蛋白质生物标志物的数据分析.
- 检查基因表达特征,微RNA概况和信号通路.
主要成果:
- 已知特征 (淋巴结状况,入侵深度) 和新生物标志物与整体存活率 (OS),无病存活率 (DFS) 和无进展存活率 (PFS) 相相关.
- 分子形状 (基因签名,miRNA) 和蛋白质生物标志物 (环素D1,TROP2,UPAR,E-cadherin) 有助于风险分层.
- 生物标志物集成增强了OSCC患者的个性化治疗策略.
结论:
- 生物标志物为改善OSCC的预后准确性提供了显著的潜力.
- 目前的临床和组织病理学参数仍然至关重要,但验证的分子概况正在出现.
- 标准化协议和前性验证对于将新生物标志物纳入临床实践至关重要.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:21Cancer Survival Analysis
626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K